- Framework of problems /
- Reasons for excluding potentially eligible studies not provided
- An umbrella review of systematic reviews on the impact of the COVID-19 pandemic on cancer prevention and management, and patient needs
| Ref ID | 893 |
| First Author | T. Muka |
| Journal | ELIFE |
| Year Of Publishing | 2023 |
| URL | https://elifesciences.org/articles/85679 |
| Keywords |
• COVID • Risk of bias • Oncology • Transparency • Protocols • Low methodological quality • Non-Cochrane reviews • Disclosure |
| Problem(s) |
• Reasons for excluding potentially eligible studies not provided • Conflicts of interest or funding of included studies not assessed • Risk of bias not incorporated into conclusions of review • Low methodological (AMSTAR) quality • No registered or published protocol |
| Number of systematic reviews included | 52 |
| Summary of Findings | From 52 included systematic reviews on impact of the COVID-19 pandemic on cancer treatment modification, delays, and cancellations indexed across PubMed and WHO COVID-19 up to November 2022. Only two reviews scored moderate to high methodological quality using AMSTAR-2, while the rest (43/52; 82.6%) were evaluated as low or critically low quality. Almost half of the included reviews (25/50; 48.0%) did not report a protocol; only 3 provided a list of excluded studies (5.7%) and just 4 reported on sources of funding of included studies (7.6%); an assessment of risk in individual studies when interpreting/discussing the results was only carried out in 8 reviews (15.3%). |
| Did the article find that the problem(s) led to qualitative changes in interpretation of the results? | N/A |
| Are the methods of the article described in enough detail to replicate the study? | No |